Triple-negative breast cancer
Oncology · 2 drugs · 5 indications
Competitive Landscape (2 drugs)
| Drug | Company | Mechanism | Modality | Route | Stage |
|---|
| Keytruda | MRK | PD-1 inhibitor | Antibody | IV | APPROVED |
| Trodelvy | GILD | TROP2-directed (SN-38 payload) | ADC | IV | APPROVED |
Indications (5)
First-line mTNBC (non-CPI)
Upcoming Catalysts
Trodelvy - 1L NSCLC - Ph3 - Topline (EVOKE-03)CLINICAL
GILDQ2 2026
Sac-TMT + Keytruda - 1L NSCLC - Ph3 - Update (OptiTROP-Lung05)CLINICAL
MRK2026
Trodelvy - 1L mTNBC - FDA ApprovalREGULATORY
GILDH1 2026
Trodelvy - 1L HR+/HER2- mBC - Ph3 - OS Data (ASCENT-07)CLINICAL
GILD2026
Trodelvy - 1L mTNBC (non-CPI) - FDA Approval (ASCENT-03)REGULATORY
GILDH2 2026
Trodelvy + Keytruda - 1L PD-L1+ mTNBC - FDA Approval (ASCENT-04)REGULATORY
GILDH2 2026
Keytruda - LOE PreparationCOMPETITIVE
MRKOngoing
Data from Supabase · Updated 2026-03-24